Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, de Vos S, Nijland M, Offner F, Andersson P-O, Brody J, Cheah CY, Prieto PG, Hellström M, Jørgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. Haematologica; https://doi.org/10.3324/haematol.2025.300086 [Early view].